Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $15

Mizuho analyst Graig Suvannavejh has maintained an Outperform rating on Immix Biopharma (NASDAQ: IMMX) and increased the price target from $14 to $15. This adjustment reflects a positive outlook for the company's performance.